Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SAB Biotherapeutics Inc (SABSW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/31/2025: SABSW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -100% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/31/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio 0.12 | 1Y Target Price - |
Price to earnings Ratio 0.12 | 1Y Target Price - | ||
Volume (30-day avg) 7308 | Beta 0.45 | 52 Weeks Range 0.01 - 0.15 | Updated Date 04/1/2025 |
52 Weeks Range 0.01 - 0.15 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.29 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3422.67% |
Management Effectiveness
Return on Assets (TTM) -78.8% | Return on Equity (TTM) -174.73% |
Valuation
Trailing PE 0.12 | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 6734232 |
Shares Outstanding - | Shares Floating 6734232 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
SAB Biotherapeutics Inc
Company Overview
History and Background
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company leveraging its DiversitAbu2122 platform to develop human polyclonal antibody therapeutics. Founded to combat emerging diseases, SAB focuses on creating targeted immunotherapies from transchromosomic cattle. SAB has evolved from preclinical research to clinical trials, primarily focused on infectious diseases and immune system disorders.
Core Business Areas
- DiversitAbu2122 Platform: SAB's core platform for generating fully-human polyclonal antibodies. This involves genetically engineering cattle to produce human antibodies in response to specific antigens.
- Therapeutic Development: Developing antibody-based therapeutics targeting infectious diseases, autoimmune disorders, and oncology. This includes research, preclinical studies, and clinical trials.
- Contract Development and Manufacturing Organization (CDMO): SAB provides manufacturing services and antibody creation services for other pharmaceutical companies.
Leadership and Structure
Eddie J. Sullivan, PhD, is the co-founder, president and chief executive officer of SAB Biotherapeutics. The company has a Board of Directors overseeing its operations and strategic direction.
Top Products and Market Share
Key Offerings
- SAB-185 (COVID-19 Therapeutic): A fully-human polyclonal antibody therapeutic designed to neutralize the SARS-CoV-2 virus. Competitors include monoclonal antibody therapies from Regeneron (REGN) and Eli Lilly (LLY), as well as antiviral drugs from Pfizer (PFE) and Merck (MRK). Market share data specific to SAB-185 is not publicly available due to the competitive landscape and changing COVID-19 treatment paradigms.
- SAB-142 (Type 1 Diabetes): A fully-human polyclonal antibody therapeutic designed to neutralize the SARS-CoV-2 virus. Competitors include monoclonal antibody therapies from Provention Bio (PRVB) and Teplizumab. Market share data specific to SAB-142 is not publicly available due to the competitive landscape.
Market Dynamics
Industry Overview
The biopharmaceutical industry is driven by innovation in drug development, especially in monoclonal and polyclonal antibody therapeutics. Key trends include precision medicine, gene therapy, and personalized immunotherapies. The infectious disease market is highly dynamic, with continuous need for new therapeutics to combat emerging pathogens and evolving variants of existing diseases.
Positioning
SAB Biotherapeutics positions itself as an innovator in the polyclonal antibody space, utilizing its DiversitAbu2122 platform to generate fully human antibodies. Its competitive advantage lies in the potential for generating more diverse antibody responses compared to monoclonal antibodies, which may lead to broader protection against pathogens. SAB is currently focused on advancing the development and commercialization of its antibody therapeutics and CDMO business.
Total Addressable Market (TAM)
The total addressable market for antibody therapeutics is estimated to be in the tens of billions of dollars annually, with significant growth expected in the coming years. SAB Biotherapeutics' TAM is aligned to the segments they are in Infectious disease, Autoimmune Disorders, and CDMO Services.
Upturn SWOT Analysis
Strengths
- DiversitAbu2122 Platform technology
- Fully-human polyclonal antibody therapeutics
- Potential for broader immune response compared to monoclonal antibodies
- Experienced leadership team
- CDMO business provides revenue stream
Weaknesses
- Clinical-stage company with no currently marketed products
- Reliance on successful clinical trial outcomes
- High cash burn rate typical of biotech companies
- Competition from established pharmaceutical companies
- Limited market awareness compared to larger competitors
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of the DiversitAbu2122 platform to new therapeutic areas
- Government funding for infectious disease research
- Increasing demand for antibody therapeutics
- Potential for expedited regulatory pathways for innovative therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing and emerging therapies
- Intellectual property challenges
- Economic downturn impacting funding for biotech companies
Competitors and Market Share
Key Competitors
- REGN
- LLY
- PFE
- MRK
- PRVB
Competitive Landscape
SAB Biotherapeutics faces intense competition from established pharmaceutical companies with greater resources and marketed products. SAB's competitive advantage lies in its innovative DiversitAbu2122 platform, which has the potential to generate more diverse and effective antibody therapeutics. However, it needs to secure partnerships and achieve clinical success to effectively compete.
Major Acquisitions
Big Stone Management
- Year: 2024
- Acquisition Price (USD millions):
- Strategic Rationale: SAB Biotherapeutics was acquired by Big Stone Management to continue development of products and platform privately. Big Stone Management took it private at $4.15 per share.
Growth Trajectory and Initiatives
Historical Growth: SAB Biotherapeutics' growth was primarily driven by clinical development milestones and securing funding for its pipeline. Its listing on the NASDAQ was short lived and was limited by available financing.
Future Projections: Future growth hinged on successful clinical trial outcomes and potential commercialization of its pipeline assets, with strong hopes that future success lies within its acquisition.
Recent Initiatives: Recent initiatives included advancing clinical trials for SAB-185 and SAB-142, as well as pursuing partnerships and collaborations to expand its platform and pipeline.
Summary
SAB Biotherapeutics is a biotech company with a unique DiversitAbu2122 platform for generating fully-human polyclonal antibodies. Historically, SAB had to deal with high cash burn and lack of funds but it has exciting product developments. SAB has since been acquired by Big Stone Management and will continue to develop its pipeline privately. The key to SAB's future success lies in its clinical trial results and any potential partnerships that can leverage its novel technology.
Similar Companies
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
REGN
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Press Releases
- Analyst Reports
- Company Website
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share estimates are approximate. The AI-based rating is based on limited information and should not be used as the sole basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About SAB Biotherapeutics Inc
Exchange NASDAQ | Headquaters Miami Beach, FL, United States | ||
IPO Launch date 2021-02-09 | CEO & Executive Chairman Mr. Samuel J. Reich | ||
Sector Healthcare | Industry Biotechnology | Full time employees 57 | |
Full time employees 57 | |||
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.